Roche and Nurix to advance potential best-in-class BTK degrader bexobrutideg
Collaboration agreement expands Roche’s oncology pipeline and offers therapeutic potential across immunology and neurology.
Roche is licensing Nurix Therapeutics’ bexobrutideg (NX-5948), a Bruton’s tyrosine kinase (BTK) degrader with best-in-class potential, through deal worth up to $2.3 billion.
The co-development and co-commercialisation agreement is set to advance clinical development targeting B-cell malignancies, with wider potential across immunology and neurology.
In immunology, this includes chronic spontaneous urticaria and multiple sclerosis in neurology.
Nurix will receive…
Already a member? Sign-in
